Efficacy and safety of celecoxib combined with JOINS in the treatment of degenerative knee osteoarthritis: study protocol of a randomized controlled trial.
Man Soo KimIn Jun KohYong Gyu SungDong Chul ParkSung Cheol YangYong InPublished in: Therapeutic advances in musculoskeletal disease (2021)
The combination treatment of the most commonly used SYSADOA drug, JOINS, and selective COX-2 inhibitor celecoxib as the representative NSAID for knee OA treatment, can be compared with celecoxib alone treatment to determine the safety or therapeutic effect.